Skip to main content
OpenTrials
Completed

NCT Number: NCT00561431

High Dose CVVHDF Compared to Standard Dose CVVHDF

In the last three decades, the mortality associated with acute renal failure (ARF) in the ICU has remained unchanged at greater than 50%, despite improvements in dialysis technology.

The primary objective is to determine whether Continuous Veno-Venous Hemodiafiltration (CVVHDF) using an ultrafiltration rate of 35 ml/hr/kg (high dose) leads to a greater reduction in all-cause ICU mortality compared to standard CVVHDF using an ultrafiltration rate of 20 ml/hr/kg.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

The University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

About this study

Although the worldwide standard for renal replacement therapy is intermittent hemodialysis(IHD), continuous renal replacement therapy (CRRT) has emerged as an alternative form of renal replacement therapy in the critical care setting due to its advantages of slow continuous fluid removal, steady acid-base correction, and hemodynamic stability.

There are no standard protocols for initiating or administering CRRT, and practice patterns vary widely among institutions, with less than 25% of patients with ARF in the ICU receiving this therapy in the United States.

Various CRRT modalities are available that use diffusion, convection, or a combination of both to obtain adequate solute clearance. However, there is no consensus as to the optimal dialysis modality, adequate dialysis dose, or optimal clearance modality (convection vs. diffusion). Clinical trials are needed to determine the optimal method of administering CRRT, with respect to modality, dose of dialysis, and time of initiation of therapy.

Although some studies suggest that a higher dose of dialysis improves survival, there have been no prospective randomized studies comparing the effectiveness of diffusion and convection, combined together, for solute clearance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female > or equal to 19 yrs of age
  • ARF defined by at least one of the following:
  • Volume overload from inadequate urine output despite diuretic agents.
  • Oliguria (urine output < 200 ml/12hrs) despite fluid resuscitation and diuretic administration.
  • Anuria (urine output < 50 ml/12 hrs).
  • Acute azotemia (BUN > or equal to 80 mg/dl).
  • Acute hyperkalemia not responsive to medication (K+ > or equal to 6.5mmol/L)
  • An increase in serum creatinine of > 2.5 mg/dl from normal values or a sustained rise in serum creatinine of > or equal to 1 mg/dl over baseline.

Exclusion criteria

  • Patients with end stage renal disease
  • Patients who have had more than one previous dialysis session for acute or chronic renal failure during the current hospitalization
  • Patient weight greater than 125 kg
  • Patient weight less than 50 kg
  • Pregnancy
  • Prisoner
  • Non-candidacy for continuous renal replacement therapy (CRRT)
  • Patient/surrogate refusal

Treatment and study plan

Standard dose of dialysis

Device

Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr

High dose of dialysis

Device

Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr

Primary outcomes

  1. Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF)

    Time frame: Up to 30 days

    The primary objective is to determine whether Continuous Venovenous Hemodiafiltration (CVVHDF) using an effluent rate of 35 ml/hr/kg (high dose) leads to an increased participant survival time as compared to CVVHDF using the standard effluent rate of 25 ml/hr/kg as measured by days on continuous renal replacement therapy (CRRT) at enrollment up to 30 days.

Secondary outcomes

  1. Recovery of Renal Function, Defined as Not Requiring Dialysis After Discontinuation of CRRT

    Time frame: Up to 30 days

    The number of participants who recover renal function at 30 days after enrollment in each arm.

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Collaborators

  • Pfizer

Registry information

Official study title

A Randomized Prospective Study Comparing High Dose Continuous Venovenous Hemodiafiltration (CVVHDF) to Standard Dose CVVHDF in Critically Ill Patients With Acute Renal Failure at the University of Alabama at Birmingham

Acronym: CVVHDF

Important dates

Study start
2003
Primary completion
2007
Study completion
2007
First posted
Nov 21, 2007
Registry last updated
Apr 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.